October 12, 2006

Solvay Seeks Approval From FDA on New Schizophrenia Drug

Pharmaceutical company Solvay SA has recently filed a new drug application with the U.S. Food and Drug Administration for a treatment it developed with Wyeth Pharmaceuticals Inc. to help schizophrenia.

The submission is based on studies that evaluated the companies' bifeprunox drug. Some 2,500 patients were evaluated for six weeks, and stable patients were evaluated for six months.

Solvay Pharmaceuticals Inc. Chief Executive Laurence Downey called the submission of bifeprunox "an important milestone in our commitment to develop and commercialize compounds that potentially address the long-term treatment outcomes of patients with mental illnesses."


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required